EP3019467A4 - Composés neurotransmetteurs hydroxyphényles - Google Patents

Composés neurotransmetteurs hydroxyphényles Download PDF

Info

Publication number: EP3019467A4
Authority: EP; European Patent Office
Prior art keywords: dihydroxyphenyl; compositions; methods; neurotransmitter; compounds
Prior art date: 2013-07-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP14822407.4A

Other languages

German (de)

English (en)

Other versions

EP3019467A1 (fr

Inventor

David S. GOLDSTEIN

Courtney Holmes

Rudolf-Giesbert Alken

Frank Schneider

Chengzhi Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Auspex Pharmaceuticals Inc

US Department of Health and Human Services

Original Assignee

Auspex Pharmaceuticals Inc

US Department of Health and Human Services

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-08

Filing date

2014-07-08

Publication date

2017-03-15

2014-07-08 Application filed by Auspex Pharmaceuticals Inc, US Department of Health and Human Services filed Critical Auspex Pharmaceuticals Inc

2014-07-08 Priority to EP19188210.9A priority Critical patent/EP3611159B1/fr

2016-05-18 Publication of EP3019467A1 publication Critical patent/EP3019467A1/fr

2017-03-15 Publication of EP3019467A4 publication Critical patent/EP3019467A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Hematology (AREA)
Otolaryngology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Anesthesiology (AREA)
Nutrition Science (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EP14822407.4A 2013-07-08 2014-07-08 Composés neurotransmetteurs hydroxyphényles Withdrawn EP3019467A4 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP19188210.9A EP3611159B1 (fr)	2013-07-08	2014-07-08	Composés neurotransmetteurs de dihydroxyphényle, compositions et procédés

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361843549P	2013-07-08	2013-07-08
US201462010098P	2014-06-10	2014-06-10
PCT/US2014/045731 WO2015006315A1 (fr)	2013-07-08	2014-07-08	Composés neurotransmetteurs hydroxyphényles

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19188210.9A Division EP3611159B1 (fr)	2013-07-08	2014-07-08	Composés neurotransmetteurs de dihydroxyphényle, compositions et procédés

Publications (2)

Publication Number	Publication Date
EP3019467A1 EP3019467A1 (fr)	2016-05-18
EP3019467A4 true EP3019467A4 (fr)	2017-03-15

Family

ID=52133230

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP19188210.9A Active EP3611159B1 (fr)	2013-07-08	2014-07-08	Composés neurotransmetteurs de dihydroxyphényle, compositions et procédés
EP14822407.4A Withdrawn EP3019467A4 (fr)	2013-07-08	2014-07-08	Composés neurotransmetteurs hydroxyphényles

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP19188210.9A Active EP3611159B1 (fr)	2013-07-08	2014-07-08	Composés neurotransmetteurs de dihydroxyphényle, compositions et procédés

Country Status (16)

Country	Link
US (5)	US20150011630A1 (fr)
EP (2)	EP3611159B1 (fr)
JP (1)	JP6567515B2 (fr)
KR (1)	KR20160041912A (fr)
CN (1)	CN105473545B (fr)
AU (2)	AU2014287418A1 (fr)
BR (1)	BR112016000338A8 (fr)
CA (1)	CA2917159C (fr)
CL (1)	CL2016000019A1 (fr)
EA (1)	EA201600093A1 (fr)
HK (1)	HK1221713A1 (fr)
IL (2)	IL243488A0 (fr)
MX (1)	MX384131B (fr)
PE (1)	PE20160556A1 (fr)
SG (2)	SG11201510764QA (fr)
WO (1)	WO2015006315A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ750392A (en) *	2016-08-30	2020-08-28	Theravance Biopharma R&D Ip Llc	Compound for use in the treatment of neurogenic orthostatic hypotension
GB2566516A (en)	2017-09-15	2019-03-20	Univ Oxford Innovation Ltd	Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
US12459965B2 (en)	2017-10-09	2025-11-04	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
BR112021018481A2 (pt)	2019-03-27	2021-11-23	Curasen Therapeutics Inc	Agonista adrenérgico beta e métodos para usar o mesmo
CN113993523A (zh)	2019-04-17	2022-01-28	指南针探路者有限公司	用赛洛西宾治疗抑郁症和其他各种病症
US11590107B2 (en) *	2019-10-25	2023-02-28	Curasen Therapeutics, Inc.	Methods for treating neurological disorders with α1A-AR partial agonists
WO2021247963A1 (fr) *	2020-06-05	2021-12-09	Senda Biosciences, Inc.	(s)-alpha-fluorométhyltyrosine en tant qu'inhibiteurs de décarboxylase pour une utilisation dans le traitement de l'hypotension

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008112773A2 (fr) *	2007-03-12	2008-09-18	Chelsea Therapeutics, Inc.	Droxidopa et composition pharmaceutique de celle-ci pour le traitement de l'hypotension véhiculée par voie neurale
WO2010054286A2 (fr) *	2008-11-10	2010-05-14	Auspex Pharmaceuticals, Inc.	Composés d'hydroxyphénylamine substitués

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0084928B1 (fr) *	1982-01-14	1985-09-11	Sumitomo Chemical Company, Limited	Procédé de préparation de thréo-3-(3,4-dihydroxyphényl)sérine
CA1223602A (fr)	1983-05-25	1987-06-30	Naohito Ohashi	Preparation de 3-(3,4-dihydroxyphenyl)-serine
JP3764179B2 (ja)	1994-07-05	2006-04-05	克寛西野	運動・意識または言語障害の機能改善剤
DE19619510A1 (de)	1995-05-18	1996-11-21	Sumitomo Chemical Co	Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin
JP3489319B2 (ja)	1996-03-12	2004-01-19	住友化学工業株式会社	カルボン酸誘導体、その製造法および用途
JPH115738A (ja)	1997-06-15	1999-01-12	Katsuhiro Nishino	脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤
US6376531B1 (en) *	1998-11-13	2002-04-23	Rupert Charles Bell	Method of treatment using deuterium compounds
DE10261807A1 (de) *	2002-12-19	2004-07-01	Turicum Drug Development Ag	Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2005084330A2 (fr)	2004-03-02	2005-09-15	Synergia Pharma, Inc.	Compositions et methodes de traitement de la congestion nasale
BRPI0708071A8 (pt) *	2006-02-17	2017-12-26	Birds Pharma Gmbh Berolina Innovative Res & Development Services	Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
ES2480966T3 (es)	2007-03-09	2014-07-29	Chelsea Therapeutics, Inc.	Droxidopa y composición farmacéutica de la misma para el tratamiento de la fibromialgia
AU2008248382B2 (en)	2007-05-07	2013-07-18	Chelsea Therapeutics, Inc.	Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
WO2008151179A2 (fr)	2007-06-04	2008-12-11	Auspex Pharmaceuticals, Inc.	Phénéthylamines substituées
US9072730B2 (en)	2009-05-14	2015-07-07	The Board Of Trustees Of The Leland Stanford Junior University	Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease
EP2450343A4 (fr)	2009-07-01	2013-01-09	Dainippon Sumitomo Pharma Co	Procédé de production de la thréo-3-(3,4-dihydroxyphényle)-l-sérine
JP5880913B2 (ja)	2011-05-17	2016-03-09	三郎佐古田	パーキンソン病の体幹症状（姿勢反射異常）の治療剤
US20130253061A1 (en)	2012-03-20	2013-09-26	Chelsea Therapeutics, Inc.	Method of droxidopa synthesis

2014
- 2014-07-08 CN CN201480042918.0A patent/CN105473545B/zh not_active Expired - Fee Related
- 2014-07-08 MX MX2016000219A patent/MX384131B/es unknown
- 2014-07-08 KR KR1020167003133A patent/KR20160041912A/ko not_active Withdrawn
- 2014-07-08 EA EA201600093A patent/EA201600093A1/ru unknown
- 2014-07-08 PE PE2016000010A patent/PE20160556A1/es unknown
- 2014-07-08 US US14/325,988 patent/US20150011630A1/en not_active Abandoned
- 2014-07-08 EP EP19188210.9A patent/EP3611159B1/fr active Active
- 2014-07-08 BR BR112016000338A patent/BR112016000338A8/pt not_active Application Discontinuation
- 2014-07-08 CA CA2917159A patent/CA2917159C/fr active Active
- 2014-07-08 WO PCT/US2014/045731 patent/WO2015006315A1/fr not_active Ceased
- 2014-07-08 JP JP2016525422A patent/JP6567515B2/ja not_active Expired - Fee Related
- 2014-07-08 EP EP14822407.4A patent/EP3019467A4/fr not_active Withdrawn
- 2014-07-08 SG SG11201510764QA patent/SG11201510764QA/en unknown
- 2014-07-08 HK HK16109787.0A patent/HK1221713A1/zh unknown
- 2014-07-08 AU AU2014287418A patent/AU2014287418A1/en not_active Abandoned
- 2014-07-08 SG SG10201800166UA patent/SG10201800166UA/en unknown
2016
- 2016-01-05 IL IL243488A patent/IL243488A0/en unknown
- 2016-01-07 CL CL2016000019A patent/CL2016000019A1/es unknown
2017
- 2017-07-21 US US15/656,035 patent/US20170319694A1/en not_active Abandoned
2018
- 2018-06-06 US US16/000,965 patent/US20180280511A1/en not_active Abandoned
- 2018-10-26 AU AU2018253594A patent/AU2018253594A1/en not_active Abandoned
2019
- 2019-05-21 IL IL266767A patent/IL266767A/en unknown
- 2019-08-01 US US16/529,187 patent/US20190374642A1/en not_active Abandoned
2021
- 2021-08-11 US US17/399,708 patent/US20220072131A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008112773A2 (fr) *	2007-03-12	2008-09-18	Chelsea Therapeutics, Inc.	Droxidopa et composition pharmaceutique de celle-ci pour le traitement de l'hypotension véhiculée par voie neurale
WO2010054286A2 (fr) *	2008-11-10	2010-05-14	Auspex Pharmaceuticals, Inc.	Composés d'hydroxyphénylamine substitués

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FOSTER A B: "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", 1 January 1985, ADVANCES IN DRUG RESEA, ACADEMIC PRESS, LONDON, GB, PAGE(S) 1 - 40, ISSN: 0065-2490, pages: 1 - 40, XP009086953 *
GOLDSTEIN DAVID S: "L-dihydroxyphenylserine (L-DOPS): A norepinephrine prodrug", CARDIOVASCULAR DRUG REVIEWS, NEVA PRESS, BRANFORD, CT, US, vol. 24, no. 3-4, 1 October 2006 (2006-10-01), pages 189 - 203, XP009107442, ISSN: 0897-5957, DOI: 10.1111/J.1527-3466.2006.00189.X *
See also references of WO2015006315A1 *

Also Published As

Publication number	Publication date
JP2016529228A (ja)	2016-09-23
HK1221713A1 (zh)	2017-06-09
IL266767A (en)	2019-07-31
WO2015006315A1 (fr)	2015-01-15
CA2917159A1 (fr)	2015-01-15
US20170319694A1 (en)	2017-11-09
HK1216747A1 (zh)	2016-12-02
SG11201510764QA (en)	2016-01-28
KR20160041912A (ko)	2016-04-18
AU2014287418A1 (en)	2016-01-28
CN105473545A (zh)	2016-04-06
EP3611159A1 (fr)	2020-02-19
AU2018253594A1 (en)	2018-11-22
PE20160556A1 (es)	2016-06-11
US20150011630A1 (en)	2015-01-08
MX384131B (es)	2025-03-14
IL243488A0 (en)	2016-02-29
US20190374642A1 (en)	2019-12-12
JP6567515B2 (ja)	2019-08-28
BR112016000338A8 (pt)	2020-01-07
EA201600093A1 (ru)	2016-08-31
SG10201800166UA (en)	2018-02-27
EP3019467A1 (fr)	2016-05-18
CL2016000019A1 (es)	2016-11-04
CN105473545B (zh)	2017-08-04
BR112016000338A2 (pt)	2017-08-22
US20180280511A1 (en)	2018-10-04
EP3611159B1 (fr)	2023-01-25
US20220072131A1 (en)	2022-03-10
CA2917159C (fr)	2022-08-23
MX2016000219A (es)	2016-05-31

Publication	Publication Date	Title
EP3035936A4 (fr)	2017-03-08	Entités chimiques, compositions et méthodes particulières
EP2992097A4 (fr)	2017-01-04	Compositions et procédés
EP2951283A4 (fr)	2017-01-25	Compositions et procédés
EP3052487A4 (fr)	2017-05-03	Compositions d'éfinaconazole stabilisée
EP3020779A4 (fr)	2017-03-08	Composition accumulatrice de chaleur
EP3102670A4 (fr)	2017-07-12	Systèmes, procédés et compositions relatifs aux combiomiques
EP2999471A4 (fr)	2017-01-25	Systèmes, procédés et compositions permettant une réticulation
EP3020778A4 (fr)	2017-01-18	Composition adhésive
IL241355B (en)	2019-03-31	Pyrazole-amide compounds, preparations containing them and their uses
IL266767A (en)	2019-07-31	Compounds, compositions and methods for making dihydroxyphenyl neurotransmitter
EP3017864A4 (fr)	2017-03-29	Composition tensioactive
EP3045053A4 (fr)	2017-03-15	Composition alimentaire
EP3013361A4 (fr)	2017-05-24	Compositions et procédés pour immunothérapie
EP3003358A4 (fr)	2017-03-22	Compositions, méthodes et dispositifs de dialyse
EP3064513A4 (fr)	2017-07-05	Composition contenant un polyrotaxane
EP3041841A4 (fr)	2017-04-19	Composé de triazolopyridine, compositions et procédés d'utilisation associés
EP3080080A4 (fr)	2017-08-16	Nouvelles compositions
EP3033392A4 (fr)	2017-04-19	Composition mécano-réactive
EP3049444A4 (fr)	2017-06-07	Systèmes, méthodes et compositions utilisés pour lutter contre des tumeurs associées à un virus
EP3009497A4 (fr)	2017-03-01	Composition nettoyante
EP3003298A4 (fr)	2017-03-22	Composés antifibrosants, méthodes et utilisations associées
EP3052604A4 (fr)	2017-03-22	Composition tensioactive
EP3038631A4 (fr)	2017-03-29	Compositions anti-inflammatoires, méthodes et utilisations correspondantes
EP3034162A4 (fr)	2017-04-05	Composition d'agent tensio-actif
EP3237399A4 (fr)	2018-08-15	Composés, compositions et procédés

Legal Events

Date	Code	Title	Description
2016-04-15	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-05-18	17P	Request for examination filed	Effective date: 20160108
2016-05-18	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-05-18	AX	Request for extension of the european patent	Extension state: BA ME
2016-10-12	DAX	Request for extension of the european patent (deleted)
2017-03-15	A4	Supplementary search report drawn up and despatched	Effective date: 20170210
2017-03-15	RIC1	Information provided on ipc code assigned before grant	Ipc: C07C 229/08 20060101AFI20170206BHEP Ipc: C07C 229/22 20060101ALI20170206BHEP Ipc: A61P 25/00 20060101ALI20170206BHEP Ipc: A61K 31/223 20060101ALI20170206BHEP
2017-06-09	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1221713 Country of ref document: HK
2017-10-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2018-02-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-03-14	17Q	First examination report despatched	Effective date: 20180209
2018-06-27	RIN1	Information on inventor provided before grant (corrected)	Inventor name: ALKEN, RUDOLF-GIESBERT Inventor name: ZHANG, CHENGZHI Inventor name: HOLMES, COURTNEY Inventor name: GOLDSTEIN, DAVID, S. Inventor name: SCHNEIDER, FRANK
2018-07-04	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: AUSPEX PHARMACEUTICALS, INC. Owner name: THE U.S.A. AS REPRESENTED BY THE SECRETARY, DEPART
2019-12-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2020-01-08	18D	Application deemed to be withdrawn	Effective date: 20190813
2023-02-03	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1221713 Country of ref document: HK